Loading
0%
Bridging basic discovery and clinical impact at China Medical University.
於中國醫藥大學，連結基礎研究與臨床應用。
We integrate molecular biology, immunology, and antibody engineering to develop therapies that can reach patients who need them most.
整合分子生物學、免疫學與抗體工程，開發真正能幫助病患的創新療法。
From CD24-targeted immunotherapy to therapeutic antibody engineering, our work spans the full translational spectrum — from bench to bedside.
從 CD24 靶向免疫治療到治療性抗體工程，我們的研究涵蓋完整的轉譯研究路徑——從實驗室到病床。
The TMS Laboratory at China Medical University focuses on translating fundamental cancer biology discoveries into therapeutic strategies. Our interdisciplinary team works at the intersection of immunology and antibody engineering to develop next-generation cancer treatments.
中國醫藥大學轉譯醫學科學實驗室專注於將基礎癌症生物學的發現轉化為治療策略。我們跨學科的團隊在免疫學與抗體工程的交叉領域開發新一代癌症治療方法。
Click to move macrophage · Space to shoot antibody toward cursor · Tag cancer cells then eat them · Boss needs 3 hits
點擊移動巨噬細胞 · 空白鍵朝游標射出抗體 · 標記癌細胞再吞噬 · Boss 需命中 3 次
CD24 is a glycoprotein overexpressed on the surface of multiple cancer types that acts as a "don't eat me" signal, shielding tumour cells from macrophage-mediated phagocytosis. By blocking the CD24 immune evasion signal, we can unleash the innate immune system to recognise and eliminate cancer cells.
CD24 是一種在多種腫瘤細胞表面過量表現的醣蛋白，透過傳送「別吃我」信號來逃避巨噬細胞的吞噬作用。阻斷 CD24 免疫脫逃訊號，可重新活化先天免疫系統，使其識別並消滅癌細胞。
POP001 is our proprietary anti-CD24 humanised monoclonal antibody engineered to block the CD24 immune evasion signalling axis. By removing the phagocytic brake on macrophages, POP001 reactivates M2 macrophage anti-tumour capacity, reverses the immunosuppressive tumour microenvironment, attenuates myeloid-derived suppressor cell accumulation, and recruits CD8⁺ T cells — driving a dual innate–adaptive anti-tumour response.
POP001 是本實驗室自主研發的抗 CD24 人源化單株抗體，專為阻斷 CD24 免疫脫逃訊號軸而設計。透過解除巨噬細胞的吞噬抑制，POP001 可活化 M2 巨噬細胞抗癌能力，逆轉腫瘤免疫抑制微環境，並弱化骨髓源性抑制性細胞的聚集，並招募 CD8⁺ T 細胞，進一步驅動先天與適應性免疫的雙重抗腫瘤反應。